JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

JNJ

176.81

-0.44%↓

NVS

122.7

+0.1%↑

ABT

133.07

+0.29%↑

TMO

477.64

+0.38%↑

ISRG

434.46

-1.69%↓

Home・Elenco Azioni・Sage Therapeutics Inc

Sage Therapeutics Inc

Aperta

SettoreSettore sanitario

8.69

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

8.69

Massimo

8.69

Dividendi
By Dow Jones
Utili prossimi	28 ott 2025

Notizie sul Sentiment di mercato

By Acuity

100%

365 / 375 Classifica in Healthcare

Sage Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

31 lug 2025, 23:56 UTC

Azioni calde

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

31 lug 2025, 23:48 UTC

Discorsi di Mercato

Scentre Can Beat Annual Earnings Guidance -- Market Talk

31 lug 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

31 lug 2025, 23:37 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

31 lug 2025, 23:37 UTC

Discorsi di Mercato

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

31 lug 2025, 23:12 UTC

Utili

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

31 lug 2025, 23:10 UTC

Utili

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

31 lug 2025, 23:09 UTC

Utili

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

31 lug 2025, 23:08 UTC

Utili

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

31 lug 2025, 23:08 UTC

Utili

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

31 lug 2025, 23:01 UTC

Utili

Amazon Posts Higher Sales, Profit -- 3rd Update

31 lug 2025, 22:08 UTC

Discorsi di Mercato

Utili

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

31 lug 2025, 22:02 UTC

Discorsi di Mercato

Utili

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

31 lug 2025, 21:57 UTC

Discorsi di Mercato

Utili

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

31 lug 2025, 21:50 UTC

Utili

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

31 lug 2025, 21:43 UTC

Utili

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

31 lug 2025, 21:29 UTC

Utili

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

31 lug 2025, 21:26 UTC

Utili

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

31 lug 2025, 21:26 UTC

Utili

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

31 lug 2025, 21:22 UTC

Utili

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

31 lug 2025, 21:19 UTC

Utili

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

31 lug 2025, 21:19 UTC

Utili

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

31 lug 2025, 21:14 UTC

Utili

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

31 lug 2025, 21:12 UTC

Utili

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

31 lug 2025, 21:10 UTC

Utili

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

31 lug 2025, 21:09 UTC

Utili

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

31 lug 2025, 21:09 UTC

Utili

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

31 lug 2025, 21:08 UTC

Utili

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

31 lug 2025, 21:08 UTC

Utili

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

31 lug 2025, 21:05 UTC

Utili

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Confronto tra pari

Modifica del prezzo

Sage Therapeutics Inc Previsione

Chi Siamo Sage Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.